Last reviewed · How we verify
BioNTech - Pfizer COVID-19 vaccine — Competitive Intelligence Brief
marketed
mRNA vaccine
SARS-CoV-2 spike protein (S protein)
Immunology / Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
BioNTech - Pfizer COVID-19 vaccine (BioNTech - Pfizer COVID-19 vaccine) — University of Birmingham. This mRNA vaccine instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response that protects against COVID-19 infection.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BioNTech - Pfizer COVID-19 vaccine TARGET | BioNTech - Pfizer COVID-19 vaccine | University of Birmingham | marketed | mRNA vaccine | SARS-CoV-2 spike protein (S protein) | |
| Heterologous mRNA booster vaccine | Heterologous mRNA booster vaccine | Tan Tock Seng Hospital | marketed | mRNA vaccine | ||
| Comirnaty Original/Omicron BA.4-5 | Comirnaty Original/Omicron BA.4-5 | Jules Bordet Institute | marketed | mRNA vaccine | SARS-CoV-2 spike protein (original strain and Omicron BA.4-5 variants) | |
| Combination BNT162b2 and BNT162b2 OMI | combination-bnt162b2-and-bnt162b2-omi | Pfizer | marketed | mRNA vaccine | SARS-CoV-2 spike protein | |
| BNT162b5 Bivalent (Original/OMI BA.4/BA.5) | bnt162b5-bivalent-original-omi-ba-4-ba-5 | Pfizer | marketed | mRNA vaccine | Spike protein of SARS-CoV-2 | |
| bivalent BNT162b2 (original/Omi BA.4/BA.5) | bivalent-bnt162b2-original-omi-ba-4-ba-5 | Pfizer | marketed | mRNA vaccine | SARS-CoV-2 virus | |
| Homologous mRNA booster vaccine | Homologous mRNA booster vaccine | Tan Tock Seng Hospital | marketed | mRNA vaccine |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (mRNA vaccine class)
- Pfizer · 12 drugs in this class
- ModernaTX, Inc. · 11 drugs in this class
- BioNTech SE · 5 drugs in this class
- Jules Bordet Institute · 5 drugs in this class
- Tan Tock Seng Hospital · 2 drugs in this class
- Clover Biopharmaceuticals AUS Pty · 1 drug in this class
- CanSino Biologics Inc. · 1 drug in this class
- Assistance Publique - Hôpitaux de Paris · 1 drug in this class
- CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
- Jens D Lundgren, MD · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BioNTech - Pfizer COVID-19 vaccine CI watch — RSS
- BioNTech - Pfizer COVID-19 vaccine CI watch — Atom
- BioNTech - Pfizer COVID-19 vaccine CI watch — JSON
- BioNTech - Pfizer COVID-19 vaccine alone — RSS
- Whole mRNA vaccine class — RSS
Cite this brief
Drug Landscape (2026). BioNTech - Pfizer COVID-19 vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/biontech-pfizer-covid-19-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab